#399 ‒ The evolution of Alzheimer's disease and dementia care: how early detection, personalized treatment, new therapies, and a multimodal approach are changing the landscape | Gayatri Devi, M.D.

Episode Summary

Executive Summary: Peter Attia interviews Dr. Gaia Devi on the rapidly evolving, highly individualized care of dementia. They frame Alzheimer’s as a spectrum disease driven by amyloid, tau, inflammation, and comorbidities; review how to diagnose subtle cases; debate biomarker testing and anti-amyloid drugs; and discuss nuanced treatment across vascular dementia, Lewy body disease, and menopause-related cognitive impairment.

Main Topics: Dementia as a spectrum, not a binary diagnosis (Priority: 5/5): Dr. Devi argues Alzheimer’s and other dementias present across a continuum influenced by brain reserve, comorbidities, and the affected brain region, making rigid staging and one-size-fits-all labels misleading. Pathophysiology and the role of inflammation (Priority: 5/5): The conversation explores the evolving model of Alzheimer’s biology: inflammation may precede amyloid, which may precede tau and synaptic failure, with neuroinflammation framed as a major future prevention target. Diagnostic strategy in high-functioning patients (Priority: 5/5): Dr. Devi outlines a layered workup for subtle cognitive decline that includes long neuropsychological testing, MRI, EEG, blood flow studies, PET scans, spinal taps, genetics, and comorbidity review. Biomarkers, APOE4, and the limits of asymptomatic screening (Priority: 4/5): They debate blood biomarkers versus CSF/PET confirmation, when to test asymptomatic people, and how APOE4 modifies risk without being fully deterministic. Anti-amyloid therapies: promise, controversy, and risk mitigation (Priority: 5/5): They discuss aducanumab, lecanemab, and donanemab, the modest clinical effect sizes, and ARIA risk management through slow titration, MRI monitoring, and steroid premedication in selected cases. Overlap among Alzheimer’s, vascular dementia, and Lewy body disease (Priority: 4/5): The discussion emphasizes mixed pathology is the rule, not the exception, and reviews how Lewy body disease is differentiated from Parkinson’s disease and treated differently. Women’s brain health, menopause, and cognition (Priority: 4/5): Dr. Devi describes menopause-related cognitive impairment, estrogen’s role in hippocampal function, and how HRT, targeted cognitive training, and neuromodulation can improve symptoms in selected women.

Key Arguments: Dementia is best understood as a spectrum of impairment rather than an all-or-nothing disease. Alzheimer’s often begins years to decades before symptoms, and inflammation may be an earlier trigger than amyloid. High-functioning patients can hide significant pathology because cognitive reserve masks decline. Diagnosis should integrate symptoms, function, biomarkers, genetics, imaging, and comorbid brain disease rather than relying on a single test. Blood biomarkers are useful but can overcall disease if interpreted without clinical context or confirmatory testing. Amyloid positivity alone is not equivalent to symptomatic Alzheimer’s, especially in older adults. Anti-amyloid drugs may be more useful earlier and in carefully selected patients than in advanced disease. ARIA risk is especially important in APOE4 homozygotes, but slow titration and close imaging may reduce harm. Most patients with dementia have mixed pathology, especially vascular disease layered on top of Alzheimer’s. Lewy body disease is frequently mistaken for Parkinson’s disease, and dopamine drugs can worsen confusion/psychosis in Lewy body patients. Menopause-related estrogen loss can mimic early Alzheimer’s and may be treatable with HRT, cognitive exercises, and TMS. The future of dementia care will likely combine early detection, personalized risk stratification, inflammation-targeted therapy, and neuromodulation.

Data Points: Aducanumab approval date: July 2021 - Dr. Devi references the controversial FDA approval timeline. Estimated incidence of ARIA in her APOE4 homozygous series: ~4% - Her slow-titration protocol for highly at-risk patients reportedly reduced imaging abnormalities. Aducanumab brain bleeding/swelling incidence discussed: >40% - She cites very high early adverse-event concern as part of why she slowed titration. Clinical benefit on CDR-SB: ~0.3–0.4 points out of 18 - She characterizes the average effect size of anti-amyloid antibodies as small. Amyloid prevalence in community adults in their 70s: ~25% - Used to caution against diagnosing Alzheimer’s from amyloid biomarkers alone. Amyloid prevalence in community adults in their 80s: 30%+ - Supports her argument that amyloid positivity is common with aging. Amyloid prevalence in community adults at age 90: ~44% - Further supports concern about false-positive interpretation in older asymptomatic people. Monoclonal antibody schedule: lecanemab: Every 2 weeks IV - Described as one of the two currently relevant anti-amyloid therapies. Monoclonal antibody schedule: donanemab: Monthly IV - Presented as an alternative with a slower titration schedule. Donanemab titration example: 350 → 700 → 1050 → 1400 mg - Her practice uses a slower ramp to reduce ARIA risk. Typical cost of anti-amyloid drugs: ~$26,000/year - Drug acquisition cost discussed, exclusive of administration and monitoring. Administration fees: $400 to $10,000 per infusion - Wide variation depending on site of care. Testing turnaround for her evaluation: 2–3 days - She compresses extensive outpatient workups for traveling patients. HRT-related estrogen threshold example: 22 pg/dL - A young woman with severe brain fog had very low estrogen despite normal FSH/LH. Historical life expectancy mention: ~50s to late 70s/early 80s - Used to explain why menopausal brain-health issues are more visible now. IVIG outcomes in her experience: 2 patients became plaque-negative; 1 stable for 17 years - She cites prior off-label immunotherapy experience in Alzheimer’s.

Pivotal Quotes: "“I feel like I'm in the field now almost as if I was an infectious disease doctor who is practicing medicine before and after penicillin was invented.”" — Dr. Gaia Devi: On how the therapeutic landscape for dementia has changed with new disease-modifying options. "“I never thought that patients with Alzheimer's could get better.”" — Dr. Gaia Devi: Her major shift in belief after biomarkers and treatment experience showed improvement/stabilization is possible. "“There is no more heterogeneous disease I can think of. No more than Alzheimer's disease.”" — Dr. Gaia Devi: On why personalized, subtype-specific treatment is necessary.

Implications: Listeners should view dementia as a treatable, heterogeneous syndrome requiring early, individualized assessment. For the field, the future points toward biomarker-guided stratification, safer anti-amyloid protocols, inflammation-focused prevention, and better recognition of mixed pathology and menopause-related cognitive decline.